^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DI Leu16 IL-2

    i
    Associations
    News

    Trials

    Company:
    Alopexx, EMD Serono, Provenance, Shenogen Pharma
    Drug class:
    CD20 inhibitor, Immunostimulant, IL-2 stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (NCT00720135)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    06/08/2015
    Initiation :
    01/01/2008
    Primary completion :
    07/01/2014
    Completion :
    07/01/2014
    CD20 • IL2
    |
    CD20 expression
    |
    Rituxan (rituximab) • DI Leu16 IL-2